PAVmed (PAVM) Competitors

$6.39 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$6.40 +0.00 (+0.08%)

As of 05/22/2026 07:47 PM Eastern

PAVM vs. TMDIF, FEMY, RVP, ICCM, and IRIX

Should you buy PAVmed stock or one of its competitors? MarketBeat compares PAVmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PAVmed include Titan Medical (TMDIF), Femasys (FEMY), Retractable Technologies (RVP), IceCure Medical (ICCM), and IRIDEX (IRIX). These companies are all part of the "medical equipment" industry.

How does PAVmed compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Titan Medical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Titan Medical's return on equity of -82.31% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
PAVmed	-21,914.12%	-146.19%	-18.39%

PAVmed has a consensus price target of $65.00, indicating a potential upside of 917.21%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 13.4% of PAVmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Titan Medical has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	1.32	$6.95M	$0.05	4.08
PAVmed	$70K	91.29	$400K	-$37.40	N/A

In the previous week, PAVmed had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for PAVmed and 0 mentions for Titan Medical. Titan Medical's average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
PAVmed	Neutral

Summary

PAVmed beats Titan Medical on 8 of the 15 factors compared between the two stocks.

How does PAVmed compare to Femasys?

Femasys (NASDAQ:FEMY) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Femasys has a beta of -2.26, suggesting that its stock price is 326% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Femasys has a net margin of -521.97% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
PAVmed	-21,914.12%	-146.19%	-18.39%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 7.6% of Femasys shares are owned by company insiders. Comparatively, 13.4% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PAVmed has lower revenue, but higher earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	11.55	-$18.63M	-$0.27	N/A
PAVmed	$70K	91.29	$400K	-$37.40	N/A

Femasys presently has a consensus target price of $5.33, indicating a potential upside of 1,117.66%. PAVmed has a consensus target price of $65.00, indicating a potential upside of 917.21%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than PAVmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Femasys had 1 more articles in the media than PAVmed. MarketBeat recorded 2 mentions for Femasys and 1 mentions for PAVmed. Femasys' average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Femasys beats PAVmed on 8 of the 15 factors compared between the two stocks.

How does PAVmed compare to Retractable Technologies?

PAVmed (NASDAQ:PAVM) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

PAVmed presently has a consensus price target of $65.00, indicating a potential upside of 917.21%. Given PAVmed's stronger consensus rating and higher possible upside, research analysts clearly believe PAVmed is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PAVmed has higher earnings, but lower revenue than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	91.29	$400K	-$37.40	N/A
Retractable Technologies	$37.15M	0.57	-$7.01M	-$0.21	N/A

In the previous week, PAVmed had 1 more articles in the media than Retractable Technologies. MarketBeat recorded 1 mentions for PAVmed and 0 mentions for Retractable Technologies. PAVmed's average media sentiment score of 0.00 beat Retractable Technologies' score of -1.00 indicating that PAVmed is being referred to more favorably in the media.

Company	Overall Sentiment
PAVmed	Neutral
Retractable Technologies	Negative

19.9% of PAVmed shares are held by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 59.5% of Retractable Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Retractable Technologies has a net margin of -41.11% compared to PAVmed's net margin of -21,914.12%. Retractable Technologies' return on equity of -17.15% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Retractable Technologies	-41.11%	-17.15%	-9.33%

PAVmed has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Summary

PAVmed beats Retractable Technologies on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, IceCure Medical had 1 more articles in the media than PAVmed. MarketBeat recorded 2 mentions for IceCure Medical and 1 mentions for PAVmed. IceCure Medical's average media sentiment score of 0.61 beat PAVmed's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IceCure Medical currently has a consensus target price of $2.09, indicating a potential upside of 789.36%. PAVmed has a consensus target price of $65.00, indicating a potential upside of 917.21%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than IceCure Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IceCure Medical has a net margin of -441.60% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
PAVmed	-21,914.12%	-146.19%	-18.39%

IceCure Medical has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

PAVmed has lower revenue, but higher earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	5.65	-$15.06M	-$0.24	N/A
PAVmed	$70K	91.29	$400K	-$37.40	N/A

Summary

PAVmed beats IceCure Medical on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and PAVmed (NASDAQ:PAVM) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

IRIDEX has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

IRIDEX has a net margin of -6.23% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat IRIDEX's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.23%	-1,204.74%	-11.16%
PAVmed	-21,914.12%	-146.19%	-18.39%

IRIDEX presently has a consensus target price of $3.00, suggesting a potential upside of 197.03%. PAVmed has a consensus target price of $65.00, suggesting a potential upside of 917.21%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PAVmed has lower revenue, but higher earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.33	-$4.44M	-$0.19	N/A
PAVmed	$70K	91.29	$400K	-$37.40	N/A

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IRIDEX had 6 more articles in the media than PAVmed. MarketBeat recorded 7 mentions for IRIDEX and 1 mentions for PAVmed. IRIDEX's average media sentiment score of 0.59 beat PAVmed's score of 0.00 indicating that IRIDEX is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IRIDEX	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IRIDEX beats PAVmed on 7 of the 13 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.36M	$7.10B	$6.46B	$12.34B
Dividend Yield	N/A	1.68%	2.76%	5.28%
P/E Ratio	-0.17	47.45	21.00	25.66
Price / Sales	91.29	73.72	558.19	86.31
Price / Cash	N/A	24.91	43.49	56.67
Price / Book	0.30	6.53	10.40	7.14
Net Income	$400K	$158.81M	$3.57B	$335.98M
7 Day Performance	-0.16%	3.61%	6.40%	4.11%
1 Month Performance	-29.00%	0.74%	3.55%	2.52%
1 Year Performance	-67.07%	3.17%	34.13%	35.04%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAVM PAVmed	2.0357 of 5 stars	$6.39 flat	$65.00 +917.2%	-67.1%	$6.36M	$70K	N/A	90	Gap Down
TMDIF Titan Medical	N/A	$0.20 -10.3%	N/A	-26.0%	$22.92M	$17.63M	N/A	50	Gap Down
FEMY Femasys	2.1398 of 5 stars	$0.36 -1.2%	$5.33 +1,387.3%	-57.9%	$21.66M	$2.38M	N/A	30	Gap Down
RVP Retractable Technologies	N/A	$0.68 +1.6%	N/A	+9.9%	$20.39M	$38.27M	N/A	240	Negative News Gap Down
ICCM IceCure Medical	3.4157 of 5 stars	$0.23 +3.6%	$2.09 +816.7%	-77.8%	$18.52M	$3.57M	N/A	60	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors

PAVM vs. TMDIF, FEMY, RVP, ICCM, and IRIX

How does PAVmed compare to Titan Medical?

Summary

How does PAVmed compare to Femasys?

Summary

How does PAVmed compare to Retractable Technologies?

Summary

How does PAVmed compare to IceCure Medical?

Summary

How does PAVmed compare to IRIDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PAVmed (PAVM) Competitors

PAVM vs. TMDIF, FEMY, RVP, ICCM, and IRIX

How does PAVmed compare to Titan Medical?

Is TMDIF or PAVM more profitable?

Do analysts prefer TMDIF or PAVM?

Do insiders & institutionals believe in TMDIF or PAVM?

Which has more volatility and risk, TMDIF or PAVM?

Which has higher earnings and valuation, TMDIF or PAVM?

Does the media prefer TMDIF or PAVM?

Summary

How does PAVmed compare to Femasys?

Which has more volatility & risk, FEMY or PAVM?

Is FEMY or PAVM more profitable?

Do institutionals and insiders believe in FEMY or PAVM?

Which has better valuation and earnings, FEMY or PAVM?

Do analysts recommend FEMY or PAVM?

Does the media prefer FEMY or PAVM?

Summary

How does PAVmed compare to Retractable Technologies?

Do analysts recommend PAVM or RVP?

Which has stronger earnings & valuation, PAVM or RVP?

Does the media refer more to PAVM or RVP?

Do institutionals & insiders hold more shares of PAVM or RVP?

Is PAVM or RVP more profitable?

Which has more volatility and risk, PAVM or RVP?

Summary

How does PAVmed compare to IceCure Medical?

Does the media refer more to ICCM or PAVM?

Do insiders & institutionals hold more shares of ICCM or PAVM?

Do analysts recommend ICCM or PAVM?

Is ICCM or PAVM more profitable?

Which has more risk & volatility, ICCM or PAVM?

Which has better valuation & earnings, ICCM or PAVM?

Summary

How does PAVmed compare to IRIDEX?

Which has more risk and volatility, IRIX or PAVM?

Is IRIX or PAVM more profitable?

Do analysts prefer IRIX or PAVM?

Which has preferable valuation & earnings, IRIX or PAVM?

Do institutionals & insiders have more ownership in IRIX or PAVM?

Does the media prefer IRIX or PAVM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools